Trovagene,Inc. (NASDAQ:TROV) Files An 8-K Other Events

Trovagene,Inc. (NASDAQ:TROV) Files An 8-K Other EventsItem 8.01 Other Events.

On August21, 2017, Trovagene,Inc. (the “Company”) issued a press release announcing compelling results of preclinical research of PCM-075 with a Histone deacetylase (HDAC) inhibitor in Non-Hodgkin Lymphoma (NHL) cell lines. A copy of the press release is furnished as Exhibit99.1 to this Form8-K.

The Company intends to conduct meetings with third parties in which its corporate slide presentation will be presented. A copy of the presentation materials is attached as Exhibit99.2 to this Current Report on Form8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d)Exhibits.

Trovagene, Inc. ExhibitEX-99.1 2 a17-20309_3ex99d1.htm EX-99.1 Exhibit 99.1     Trovagene’s PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines   Additionally,…To view the full exhibit click here
About Trovagene,Inc. (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.